Podcasts about Fibrosis

One in three adults now has fatty liver disease, and most don't even know it. It's become the most common form of liver dysfunction worldwide—even outpacing alcohol-related liver damage. And the real danger? It often progresses in silence, from fat to inflammation to fibrosis, with no symptoms until it's too late.In this episode of ReInvent Healthcare, Dr. Ritamarie exposes a quiet transformation that's becoming alarmingly common: the metabolic cascade behind fatty liver. It doesn't start with pain or obvious signs. It starts with subtle shifts in biochemistry that most protocols completely miss.Before the liver scars, there are clues. And if you know where to look, you can help reverse the damage long before it becomes permanent.What's Inside This Episode? Why liver damage is now driven more by food than by alcoholThe signals that mark the shift from fat accumulation to fibrosisWhat “normal” AST and ALT might be hiding, and how to interpret themA critical lab ratio that reveals what single values can'tEarly metabolic signs that point to liver inflammation before imaging shows a thingTherapeutic strategies to restore liver function, starting with the kitchenHow trauma and oxytocin tie into liver recoveryThe botanical allies that protect and regenerate hepatic tissueResources and Links:Download our FREE Metabolic Health Guide here. Check out the FREE From Fat to Fibrosis Practitioner Quick GuideHere is a FIB-4 Calculator Tool FIB-4 = (Age × AST) / (Platelets × √ALT)NAFLD fibrosis score (NFS) = -1.675 + (0.037 × age) + (0.094 × BMI) + (1.13 × hyperglycemia) + (0.99 × AST/ALT ratio) - (0.013 × platelet count) - (0.66 × albumin)Join the Next-Level Health Practitioner Facebook group here for free resources and community supportVisit INEMethod.com for advanced health practitioner training and tools to elevate your clinical skills and grow your practice by getting life-changing results. Check out other podcast episodes here

Dr. Jack Cush reviews the news and journal articles from RheumNow.com.  Pool therapy, Fibrosis, NSIE's and whats best for knee OA.

Listen to this podcast to learn more about Fibrosis Dysplasia. Want to know more about Oral diseases? Follow us on Instagram: @Doencasdeboca

Send us a textAging, tissue repair, and the longevity benefits of psilocin.Episode Summary: Dr. Louise Hecker discusses her research on tissue repair and regeneration, explaining how fibroblasts drive wound healing by forming scar tissue but fail to resolve properly with age, leading to fibrotic diseases like pulmonary fibrosis and liver cirrhosis; they discuss aging hallmarks such as oxidative stress and telomere shortening, and highlight Hecker's study showing psilocybin's active metabolite, psilocin, extends cellular lifespan in lab cultures by reducing oxidants and preserving telomeres, while monthly doses in aged mice improved appearance and survival rates.About the guest: Louise Hecker, PhD is an Associate Professor of Medicine at Baylor College of Medicine, specializing in repair and regeneration processes, particularly in aging and fibrotic diseases.Discussion Points:Fibroblasts are dormant cells that activate during injury to pull wounds closed and form scars, then de-differentiate or die; aging impairs this, causing persistent scarring and disease.Aging reduces the body's regenerative capacity; different organs vary in repair efficiency, with skin healing better than heart tissue.Oxidative stress, like "rust" in the body, accumulates with age due to imbalanced reactive oxygen species production and antioxidant defenses, contributing to cellular damage.Telomeres act as protective DNA caps that shorten with cell divisions, serving as a hallmark of biological aging; sirtuins are master regulators influencing aging processes.Hecker's in vitro study showed psilocin dose-dependently extended fibroblast lifespan by 29-50%, lowering oxidative stress below young cell levels and preserving telomeres.In aged mice (equivalent to 60-65 human years), monthly high-dose psilocybin (15 mg/kg) led to healthier appearance, regrown fur, and 80% survival when controls reached 50% mortality after 10 months.Psilocybin's effects may stem from serotonin receptors expressed in many cell types beyond the brain, suggesting broader anti-aging potential; future work explores mechanisms, optimal dosing, and applications for age-related diseases.Fungi like magic mushrooms represent an under-explored "kingdom" for medicine, with psilocybin's durable effects hinting at systemic impacts on aging.Reference Paper:Study: Psilocybin treatment extends cellular lifespan and improves survival of aged miceRelated content:Support the showAffiliates: Seed Oil Scout: Find restaurants with seed oil-free options, scan food products to see what they're hiding, with this easy-to-use mobile app. KetoCitra—Ketone body BHB + electrolytes formulated for kidney health. Use code MIND20 for 20% off any subscription (cancel anytime) Lumen device to optimize your metabolism for weight loss or athletic performance. Code MIND for 10% off SiPhox Health—Affordable at-home blood testing. Key health markers, visualized & explained. Code TRIKOMES for a 20% discount. For all the ways you can support my efforts

Deepak Srivastava, MD, explores how cellular reprogramming offers new hope for treating heart disease. He highlights innovative strategies to regenerate damaged heart tissue by stimulating adult cardiomyocytes to divide and converting fibroblasts into heart-like cells. His team develops a nonviral delivery system using lipid nanoparticles and investigates the role of specific gene regulators in restoring heart function in animal models. Srivastava also discusses a potential oral therapy for aortic valve disease, driven by insights into cellular fate changes caused by NOTCH1 mutations and telomere shortening. Additionally, he reveals how trisomy 21 may trigger congenital heart defects by altering the identity of specialized heart cells. Through pioneering research in genetics and regenerative medicine, Srivastava demonstrates how understanding developmental biology can lead to transformative clinical advances. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40447]

Deepak Srivastava, MD, explores how cellular reprogramming offers new hope for treating heart disease. He highlights innovative strategies to regenerate damaged heart tissue by stimulating adult cardiomyocytes to divide and converting fibroblasts into heart-like cells. His team develops a nonviral delivery system using lipid nanoparticles and investigates the role of specific gene regulators in restoring heart function in animal models. Srivastava also discusses a potential oral therapy for aortic valve disease, driven by insights into cellular fate changes caused by NOTCH1 mutations and telomere shortening. Additionally, he reveals how trisomy 21 may trigger congenital heart defects by altering the identity of specialized heart cells. Through pioneering research in genetics and regenerative medicine, Srivastava demonstrates how understanding developmental biology can lead to transformative clinical advances. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40447]

Deepak Srivastava, MD, explores how cellular reprogramming offers new hope for treating heart disease. He highlights innovative strategies to regenerate damaged heart tissue by stimulating adult cardiomyocytes to divide and converting fibroblasts into heart-like cells. His team develops a nonviral delivery system using lipid nanoparticles and investigates the role of specific gene regulators in restoring heart function in animal models. Srivastava also discusses a potential oral therapy for aortic valve disease, driven by insights into cellular fate changes caused by NOTCH1 mutations and telomere shortening. Additionally, he reveals how trisomy 21 may trigger congenital heart defects by altering the identity of specialized heart cells. Through pioneering research in genetics and regenerative medicine, Srivastava demonstrates how understanding developmental biology can lead to transformative clinical advances. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40447]

Deepak Srivastava, MD, explores how cellular reprogramming offers new hope for treating heart disease. He highlights innovative strategies to regenerate damaged heart tissue by stimulating adult cardiomyocytes to divide and converting fibroblasts into heart-like cells. His team develops a nonviral delivery system using lipid nanoparticles and investigates the role of specific gene regulators in restoring heart function in animal models. Srivastava also discusses a potential oral therapy for aortic valve disease, driven by insights into cellular fate changes caused by NOTCH1 mutations and telomere shortening. Additionally, he reveals how trisomy 21 may trigger congenital heart defects by altering the identity of specialized heart cells. Through pioneering research in genetics and regenerative medicine, Srivastava demonstrates how understanding developmental biology can lead to transformative clinical advances. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40447]

Deepak Srivastava, MD, explores how cellular reprogramming offers new hope for treating heart disease. He highlights innovative strategies to regenerate damaged heart tissue by stimulating adult cardiomyocytes to divide and converting fibroblasts into heart-like cells. His team develops a nonviral delivery system using lipid nanoparticles and investigates the role of specific gene regulators in restoring heart function in animal models. Srivastava also discusses a potential oral therapy for aortic valve disease, driven by insights into cellular fate changes caused by NOTCH1 mutations and telomere shortening. Additionally, he reveals how trisomy 21 may trigger congenital heart defects by altering the identity of specialized heart cells. Through pioneering research in genetics and regenerative medicine, Srivastava demonstrates how understanding developmental biology can lead to transformative clinical advances. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40447]

Deepak Srivastava, MD, explores how cellular reprogramming offers new hope for treating heart disease. He highlights innovative strategies to regenerate damaged heart tissue by stimulating adult cardiomyocytes to divide and converting fibroblasts into heart-like cells. His team develops a nonviral delivery system using lipid nanoparticles and investigates the role of specific gene regulators in restoring heart function in animal models. Srivastava also discusses a potential oral therapy for aortic valve disease, driven by insights into cellular fate changes caused by NOTCH1 mutations and telomere shortening. Additionally, he reveals how trisomy 21 may trigger congenital heart defects by altering the identity of specialized heart cells. Through pioneering research in genetics and regenerative medicine, Srivastava demonstrates how understanding developmental biology can lead to transformative clinical advances. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40447]

Deepak Srivastava, MD, explores how cellular reprogramming offers new hope for treating heart disease. He highlights innovative strategies to regenerate damaged heart tissue by stimulating adult cardiomyocytes to divide and converting fibroblasts into heart-like cells. His team develops a nonviral delivery system using lipid nanoparticles and investigates the role of specific gene regulators in restoring heart function in animal models. Srivastava also discusses a potential oral therapy for aortic valve disease, driven by insights into cellular fate changes caused by NOTCH1 mutations and telomere shortening. Additionally, he reveals how trisomy 21 may trigger congenital heart defects by altering the identity of specialized heart cells. Through pioneering research in genetics and regenerative medicine, Srivastava demonstrates how understanding developmental biology can lead to transformative clinical advances. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40447]

Send us a textThis discussion on ways to improve MASH patient management comes from the early July roundtable on "Major Issues of the First Six Months of 2025." As a reminder, that roundtable included the three co-hosts (Louise, Jörn Schattenberg and Roger Green) Louise drives this conversation based on two related issues she sees emerging: (i) increasing opportunities for motivated patients to manage their own health and (ii) managing the total patient in an environment where people may be taking incretin agonists as if they are consumer drugs. With increased access to scanning, providers can monitor patients (and patients can self-monitor) more closely. However, some of the issues a provider might find are tricky: patients who undertake what Louise describes as "the sneaky areas patients think are normal, but are probably contributing to disease" due to miseducation or no education on healthy eating and lifestyle, or patients purchasing and using incretin agonists through consumer channels, but possibly at subtherapeutic doses. Vigilance and probing are key here, but health systems will need to train more people on the types of probing that uncover underlying issues and behaviors that patients mistakenly believe to be healthy. The discussion also extends to the role of NITs in diagnosis and patient management, and how providers need to shift the paradigm away from describing a patient by fibrosis stage and instead focus on the amount of fat in the liver and its overall suppleness.

Send us a text00:00:00 - Surf's Up, Season 6, Episode 12This week's episode is a special three-part roundtable on the implications of the FDA's recent approval of semaglutide. Naim Alkhouri, Manal Abdelmalek, Scott Isaacs and Zobair Younossi join Roger Green in a discussion that focuses less on specifics of pharmacotherapy and more on how having two drugs available will change MASH management in the US.00:08:45 - Part I: How Will The Semaglutide Approval Affect Patient Treatment and Pharmacotherapy?The group starts by describing the sense of "enthusiasm" and "fulfillment" hepatology drug developers feel to see two drugs approved in the US and many other major changes to come (more drug approvals, FDA acceptance of a path to approval that is not based on liver biopsy). One interesting takeaway is that while the approval of semaglutide will likely change the number of patients treated with MASH pharmacotherapy, the greater impact of this approval will be on public awareness of MASH and the accompanying demand for treatment. In terms of actual drug use, the first major change will come among patients living with obesity but not Type 2 diabetes. Most of these patients previously saw their semaglutide prescriptions rejected for payment by health insurers. However, many of these patients will be living with MASH, and they are likely to see their prescriptions approved. Instead, the largest impact may involve increased education and awareness. Scott pointed out that endocrinologists, who frequently prescribe incretin agonists, will have reason to learn how to diagnose and manage MASH in patients they already treat. Zobair noted that an array of companies, starting with pharmaceutical manufacturers and scanning companies, will dramatically increase investments in prescriber and patient education.00:25:30 - Part II: How the Structure of Medical Practice Is Likely To ChangeNaim states that many hepatologists are currently uncomfortable managing patients on GLP-1 agonists. This will need to change. Manal points out that providers must check for cirrhosis when testing for MASH and understand how to respond accordingly. An increase in the number of providers having access to in-office scanning devices will facilitate this process. Zobair states that even if all related specialists integrate MASH into their practices, the actual patient care demand will require alternative pathways in which the responsibility for patient care will rest with specialist APPs. After Naim Alkhouri describes some of the differences between resmetirom and semaglutide in terms of practical treatment decisions, the discussion focuses on why MASLD and MASH will create unique challenges for hepatology practices. Manal views the issue as a matter of time; practices cannot absorb large numbers of new, non-urgent patients. Naim suggests that the real issue is the business question: specialists today do not profit simply from treating patients. Zobair agrees with Naim and notes that the challenge is not unique to hepatology. He expresses the hope that AI and efficient database management will make it easier to target patients, screen, diagnose and treat them. 00:44:17 - Part III: What Happens Next?In this final section, panelists identify some of the changes they foresee if we are to manage the tsunami of undiagnosed MASLD patients. Many of the comments touch on themes discussed earlier in this episode, but a couple are unique. Zobair states we must remember that the vast majority of MASLD patients will never develop MASH. Manal foresees a more sophisticated approach to selecting pharmacotherapies as prescribers have a broader set of options, each with its own benefits and drawbacks. Scotts anticipates a "paradigm shift" in which providers come to view MASH similarly to how they view diabetic comorbidities. 

The FDA has granted accelerated approval to semaglutide (Wegovy) as the first drug for metabolic dysfunction–associated steatohepatitis (MASH), showing significant improvements in liver health and weight loss in the phase 3 ESSENCE trial. A systematic review of acetaminophen use in pregnancy found potential risks with long-term or frequent use but confirmed short-term, low-dose use remains appropriate when needed. Finally, an AI model integrating MRI, biomarkers, and clinical data improved prediction of knee osteoarthritis progression, enhancing physician accuracy and suggesting future support for earlier, personalized interventions.

If you're curious as to if you have any stored emotions or trauma that might be causing your illness, preventing you from achieving your or even just showing up as the best, authentic version of yourself, I invite you to take my free Stored Emotions and Trauma Quiz How often do you think about your kidneys?In this episode, I sit down with Dr. Robin Rose, a longtime voyager and pioneer in conscious and holistic healing whose path went from nursing to nurse practitioner to medical school. Her passion for kidney health was sparked by her own experience with kidney cancer and kidney disease, and the decade-long recovery that led her to a new paradigm she calls phenology, the art and clinical science of kidney success.We talk about exactly what to look for in labs (including how to think about GFR), the emotional and spiritual energetics behind kidney dysfunction, and the top lifestyle moves to make when kidney function isn't where it should be. We also get into why kidneys are so often overlooked in medicine and how Dr. Rose rebuilt her health after a nephrectomy. You'll Learn:Labs to consider for assessing kidney healthWhat a healthy GFR level isEnergetics, emotional, and spiritual aspects underlying kidney dysfunction and diseaseTop 10 lifestyle changes for poor kidney functionThe hidden early signs of kidney decline most doctors missHow conventional and even functional medicine often overlook kidney healthKey lifestyle shifts that can improve kidney performance and energy levelsThe quiet damage high animal protein diets can cause in compromised kidneysWhat it feels like to rebuild health after losing a kidneyHow spiritual practices and mindset can influence physical healingThe overlooked role of kidney tubules and how to test their functionPractical ways to reduce kidney-toxic exposures in daily lifeTimestamps: [00:00] Introduction [05:44] Robin shares her journey through illness, surgery, and kidney cancer diagnosis [14:59] Discovering functional and regenerative approaches to improve GFR [24:53] Emotional, spiritual, and energetic aspects of kidney health [34:27] Why kidneys are often overlooked in conventional and functional medicine [42:58] Understanding kidney tubules and overlooked testing options [53:22] Diet changes that protect kidney function and common mistakes to avoid [1:02:47] Reducing toxins and environmental exposures that harm kidneys [1:12:55] Mindset, self-love, and adapting to support long-term healing [1:21:40] Key lifestyle factors for kidney regeneration and successResources Mentioned:Renology Peptides by Robin Rose | BookLearn more from Robin by checking out her websiteFind More From Dr. Stephanie Davis:Dr. Stephanie Davis | WebsiteQuantum Rx | InstagramQuantum Rx | Skool

Send us a textThis week's expert interview is with Dr. Emily Andaya, Medical Director of the Cardiovascular Program at Major Health Partners of Shelbyville, IN. She joins Louise Campbell and Roger Green to discuss the American Heart Assocation's CKM initiative, why she believe it should be titled "CKLM" for liver, and how including liver in the CKM scoring system would make it stronger and provide a more robust tool to help improve patients' health. Emily begins by discussing her attendance at the American Society for Preventive Cardiology meeting in Boston the previous weekend, where Dr. Christos Montzoros presented a talk proposing that the liver's role in cardiovascular diseases is "equally critical" compared to the kidney and other multi-metabolic co-morbidities. Dr. Montzoros closed his talk by stating that the CKM syndrome description should be changed to CKLM to reflect the importance of the liver, and that the CKLM patient scoring and criteria should reflect this as well.Next, Emily describes the 0-to-4 scoring system that the CKM initiative has chosen to use and the recommendations that accompany the scoring system itself. The system does not neatly overlay the 4-point fibrosis scoring system or the NAS score, but Emily describes how these might be incorporated into the CKM score. The conversation shifts to focus on patient management. Since the original CKM paper was published in 2023, resmetirom had not yet been approved and the paper itself focused more on screening than on treatment. To Emily, adding the "L" to CKM would entail adding resmetirom to treatment protocols as appropriate, and also considering drug combinations that addressed liver disease. Louise takes this issue from the other side, suggesting that every time a provider prescribes a drug to a CKM patient, the potential for negative liver effects should be part of the selection process. Emily and Louise agree that providers and patients should take a holistic approach to therapy for these patients. One benefit: even if a patient has multiple organs affected by multi-metabolic challenges, the provider can educate the patient that there is a single target disease to treat instead of multiple different diseases. As Roger notes, treating 4-5 discrete diseases simultaneously sounds overwhelming, while treating one overarching disease sounds far more manageable.The conversation ends with a focus on whether we are correctly identifying high-risk cardiovascular patients in the current environment, and how this more holistic focus might improve patient screening and identification.

Send us a textMulti-Metabolic Week focuses on the idea that MASLD and MASH are elements in a systemic set of Multi-Metabolic issues. This conversation is the first of two looking at the concept of the "Multi-Metabolic Clinic," a clinic that treats the entire spectrum of multi-metabolic diseases. The core of this episode starts during the weekly groundbreaker exercise, during which our guests began to describe the path that brought them from single-disease specialization to the broader multi-metabolic practice.. Immediately after the groundbreakers, participants describe their clinics today, including patient population and principles underlying their approach to treatment. For Karen, the path started in a conventional gastrointestinal practice. A decade ago, she gained certification in obesity medicine. While treating patients for obesity, she came to appreciate the interplay of obesity, diabetes and the other manifestations of multi-metabolic disease. Eventually, she divided her practice and time so that she spent half her time in the GI practice and the other half creating Trajectory Health Partners, a practice focused on overall metabolic health.For Dr. López, the initial goal was to "re-educate the hypothalamic problem," which he saw as the root cause of obesity and from which all other metabolic issues came. He describes this as "the auto-destruction button" of patients' lives, leading to two causes of death: (1) insulin resistance and related cardiovascular problems, and (2) short-telomere cancers. The rest of this conversation focuses on the tests that the two clinics use to confirm MASLD or MASH and their approaches to treating multi-metabolic patients.

Send us a text00:00 - Surf's Up 6.10.1This conversation covers three topics. Jörn Schattenberg discusses two papers that suggest an exciting role NITs might play in future prescribing decisions, two executives from LiverRight describe the U.S.'s first virtual liver clinic, and Tom Jobson of Predictive Health Intelligence updates us on how simple analyses of large data bases can identify and motivate high-risk liver patients to visit their doctors. 00:17:30 - Roundtable: NITs might help physicians determine the value of metabolic vs. specific anti-fibrotic effects for individual patientsThe overall theme of this roundtable is "Major Stories and Events of the First Half, 2025." Jörn's contribution is to discuss two papers that use proteomic analyses to determine the degree to which a patient's MASH is driven by metabolic issues as compared to direct fibrotic challenges. Today, when we have only a few drugs, limited NITs and no proteomic tests available for use in practice, these findings point to directions for future research and test development. Over time, providers may be able to prescribe based on the knowledge of h0w much benefit metabolic agents might provide as compared to anti-fibrotics. This may point to step therapy or multi-agent first line therapy, but it is an exciting idea.00:29:50 - Newsmakers: LiverRight opens America's first virtual liver clinic LIverRIght CEO Brandon Tudor and Chief Medical Officer Alexander Lalos join Roger Green to discuss the launch of America's first virtual hepatology clinic. Brandon shares his personal history to explain why providing fast access is so important to him. Alex describes his original motivation to go into Transplant Hepatology and how, over time, his focus has shifted from healing the sick to preventing disease in the first place. They describe how LiverRight works and their successes to date in reducing patients' time from first contact to visit, often from months to days. NOTE: Roger Green is a paid advisor to LiverRight.00:56:44 - Expert: Tim Jobson describes how Hepatoscope is helping the NHS identify untreated high-risk liver patients and bring them to the office for screening. Tim describes hepatoSIGHT, a tool that "allows clinicians to get their hands on the data and to find patients both for treatment and for clinical trials."  He describes it as standard in Somerset, UK, now, and proceeds to share new data about the patient experience. This is a unique program in that providers reach out to tell individual patients they should visit the physician based on information found in their medical records. Interestingly, patient response is overwhelmingly positive. Six in ten respondents rated their satisfaction with the process, giving it a mean of 4.8 on a 5-point scale. Tim also shared some preliminary modeling suggesting that sustained use of hepatoSIGHT could increase clinical trial participation as much as 50-fold if trial sites had the capacity to take all these patients. In all, this is a warming, affirming look at whether and how patients know they benefit from what we ask them to do and share.   01:29:58 - ConclusionThe business report discusses the next few episodes and asks who would like to meet Roger at Paris MASH.

Send us a textThis conversation is the fourth and final segment of SurfingMASH's April discussion of drug development in memory of Stephen A. Harrison. In addition to co-hosts Jörn Schattenberg, Louise Campbell and Roger Green, panelists include hepatologist and key opinion leader Sven Francque. The discussion focuses on PPARs, genetic medicines, and other emerging drug classes while considering the idea that drug therapies can have an impact on the liver independent of their effect on fibrosis regression. It begins with Sven  discussing his experience as a lead investigator in clinical trials for the pan-PPAR agonist lanifibranor, whose Phase 3 trial is now fully recruited. Sven states that in addition to fibrosis regression, lanifibranor is likely to exhibit other pleiotropic effects, and notes that vascular changes start early in the fibrotic progression process. After Sven elaborates on these effects, Louise asks about the SCD-1 agent Aramchol. This leads to a discussion about the idea that over time, therapy will probably come to incorporate two separate modes of action, with one to treat the metabolic dysfunction and the other to treat specific effects in the liver or, as Jörn puts it, "combining weight-neutral and weight-reducing drugs." This evolves into a discussion of what Louise terms "personal-centric" medicine, or what patient advocate Mike Betel has previously described on SurfingMASH as "tailored medicine."The rest of the conversation predominantly lists other classes of drugs, "safe" mitochondrial uncouplers, genetic medicines, and others. Roger inquires about the FASN inhibitors, which are entering Phase 3 clinical trials. Jörn says that the data appears positive and unique. That said, he and Sven agree we need more data.Louise sounds the closing note for this roundtable by discussing our co-founder, Stephen Harrison, and the energy and enthusiasm he brought to the entire drug development process. The group agrees that Stephen's impact continues to be felt through the MASLD community, even as he is missed by us all.

Send us a textThis conversation is the third segment of SurfingMASH's April discussion of drug development in memory of Stephen A. Harrison. In addition to co-hosts Jörn Schattenberg, Louise Campbell and Roger Green, panelists include hepatologists and key opinion leaders Sven Francque and Naim Alkhouri. Louise starts the discussion by asking when a patient is metabolically and hepatically healthy instead of merely driving weight loss. She notes that basing therapy entirely on weight loss goals will breed failure and frustration while failing to address the actual pivotal goal of metabolic health. Sven agrees and notes how important this point is. Roger suggests that the benefit of weight loss is likely to become limited over time, which is why there is such excitement about GLP-glucagon combination therapies. Again, Sven concurs, noting that such knowledge and increasing drug class diversity will allow researchers to look at true, basic differences between agents instead of "small numerical differences."Jörn notes the importance of NITs in addressing these kinds of issues. Scanning is an effective method for measuring changes in liver fat; however, the academic community has developed surrogate NITs for specific physiological activities. As Sven notes, there is still a great deal of work to do here. That said, Jörn cites examples of large, NIT-based projects like the VCTE Study Group that have sufficient sample size to start building definitions around kilopascal levels. Louise shares her strong concern that many TE operators are not trained adequately to appreciate subtle clues that would tell an expert how an individual scan was providing misleading results. She notes that the increased demand for scanning, in this case TE, is going to drive a watering down of the qualifications and the skill of the user and the supervision level..." The discussion winds down with Sven agreeing with Louise and stating the need for sequential testing and Jörn citing EASL guidelines in stating that practices should provide and manage high-quality care to the best of their abilities. 

Exciting new insights from Science Translational Medicine (2025)!   Researchers uncovered how the GAS6–AXL–FAK axis determines whether wounds heal with scars or regeneration.

La contractura de Dupuytren empeora lentamente con el transcurso de los años. La afección comienza con un bulto firme en la palma de la mano, que puede ser doloroso.

After surgery like facelifts, tummy tucks, liposuction, or BBLs, swelling and stiffness can stick around. Lymphatic drainage can make a big difference in your recovery. Planning your post-op care ahead of time is just as important as choosing the right procedure, and not all lymphatic massages are the same. To support healing, you need someone who truly understands the lymphatic system. A qualified therapist with the right training can help you recover safely and more effectively.Many people claim to be lymphatic specialists but lack proper credentials. Board-certified massage therapist and lymphedema expert Kathleen Lisson explains how to find the right lymphatic drainage therapist and what to ask before letting someone treat you.Kathleen explains why surgeons and therapists need to work together during recovery, and she sets the record straight on home massages and lymphatic therapy devices.LinksFollow Kathleen on Instagram @kathleenlissonPurchase Kathleen's Plastic Surgery Recovery HandbookSubscribe to Kathleen's YouTube @KathleenHelenLissonLearn from the talented plastic surgeons inside La Jolla Cosmetic, the 20x winner of the Best of San Diego and global winner of the 2020 MyFaceMyBody Best Cosmetic/Plastic Surgery Practice.Join hostess Monique Ramsey as she takes you inside La Jolla Cosmetic Surgery Centre, where dreams become real. Featuring the unique expertise of San Diego's most loved plastic surgeons, this podcast covers the latest trends in aesthetic surgery, including breast augmentation, breast implant removal, tummy tuck, mommy makeover, labiaplasty, facelifts and rhinoplasty.La Jolla Cosmetic is located just off the I-5 San Diego Freeway at 9850 Genesee Ave, Suite 130 in the Ximed building on the Scripps Memorial Hospital campus.To learn more, go to LJCSC.com or follow the team on Instagram @LJCSCWatch the LJCSC Dream Team on YouTube @LaJollaCosmeticThe La Jolla Cosmetic Podcast is a production of The Axis: theaxis.io 

Contributor: Ricky Dhaliwal, MD Educational Pearls: What factors are considered in a COVID-19 infection? The viral load: Understood as the impact of SARS-CoV-2 viral particles infecting host cell tissue itself (utilizing ACE-2 receptors). Pro-Inflammatory Response: Post-infection, the body's downstream systemic cytokine release (can be both normal or hyperactive, aka “cytokine storm”). What cardiac impacts have been observed with COVID-19? Arrhythmias: The mechanism of COVID-19 infection and arrhythmias is believed to be multifactorial. However, evidence suggests T-cell-mediated toxicity and cytokine storm may contribute to cardiac myocyte damage, precipitating proarrhythmias instead of direct viral entry. Bradycardia: Increased prevalence in patients with severe COVID-19 infection, but not associated with increased adverse outcomes. Atrial Fibrillation: Most common cardiac complication and risk factor for worsened outcomes in patients with COVID-19. Biggest associated risk is strokes, and may require heightened monitoring and anticoagulation therapy to mitigate stroke risk. Fibrosis of Cardiac Tissue: Similar to arrhythmias, believed to be inflammation-mediated in COVID-19. Fibrosis of cardiac tissue increases the risk that any arrhythmias that develop during infection may persist after the infection has resolved. Ventricular damage: Also inflammation mediated by an active infection and contributes to myocarditis. No evidence suggests that COVID-19 vaccination contributes to myocarditis.  Sinus node dysfunction induced by inflammation that may lead to or be similar to Postural Orthostatic Tachycardia Syndrome (POTS).  Big takeaway? Patients who have had or currently have COVID-19 are at an increased risk of developing arrhythmias and sustaining them post-infection. However, a majority of patients will recover. Due to atrial fibrillation being the most prevalent arrhythmia associated with COVID-19 infection, increased monitoring and potential anticoagulation therapy are required.  References Gopinathannair R, Olshansky B, Chung MK, Gordon S, Joglar JA, Marcus GM, et al. Cardiac Arrhythmias and Autonomic Dysfunction Associated With COVID-19: A Scientific Statement From the American Heart Association. Circulation. 2024 Nov 19;150(21):e449–65. Khan Z, Pabani UK, Gul A, Muhammad SA, Yousif Y, Abumedian M, et al. COVID-19 Vaccine-Induced Myocarditis: A Systemic Review and Literature Search. Cureus. 14(7):e27408. Summarized by Dan Orbidan, OMS1 | Edited by Dan Orbidan & Jorge Chalit, OMS3 Donate: https://emergencymedicalminute.org/donate/

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let's dive into the latest updates impacting clinicians and healthcare providers like you! Interested in a more traditional, text rundown? Check out the HCPFive! Top 5 Healthcare Headlines for April 21-April 27, 2025: FDA Approves Pz-cel (Zevaskyn) Gene Therapy for RDEB The FDA has approved pz-cel, the first autologous gene therapy for RDEB, following pivotal Phase 3 data demonstrating efficacy and safety in wound healing. FDA Approves Upadacitinib, Expanding Treatment for Adults With Giant Cell Arteritis Upadacitinib has been approved for giant cell arteritis, supported by Phase 3 data showing its potential to induce sustained remission and reduce corticosteroid reliance. FDA Approves Nipocalimab Generalized Myasthenia Gravis for Adults, Children Nipocalimab received FDA approval for gMG in antibody-positive patients aged ≥12, expanding therapeutic options across major serotypes. Semaglutide Improves Steatohepatitis, Fibrosis in Phase 3 MASH Trial Phase 3 trial results show semaglutide significantly improves steatohepatitis and fibrosis markers in patients with MASH, without worsening liver histology. Increased Fasting Blood Glucose Triples Risk of Heart Damage in Adolescents International data links elevated fasting glucose and insulin resistance in adolescence to markedly increased future risk of heart damage, especially among females.

Semaglutide 2.4 mg weekly led to significant resolution of MASH and reduction in fibrosis after 72 weeks

Commentary by Dr. Jijun Huang.

This week's expert, Hepatologist and Key Opinion Leader Scott Friedman, joins Roger to discuss advances in acceptance of gene therapy and knowledge in other areas of basic liver science. When discussing science, he pays particular attention to findings on the diversity of stellate cells and his interest in CAR-T as a therapy for liver disease.This conversation starts with Scott discussing gene therapy. Specifically, he applauds the idea that gene therapy is  becoming accepted in many diseases after a faulty start years ago, due to an unfortunate patient death in a badly controlled trial.  He comments that this acceptance has unique benefits in liver disease because the liver can regenerate so much faster and more efficiently than other organs. He mentions some of the rare liver diseases in which patients are benefiting from gene therapy, and notes that we now have gene therapies and early-stage trials to target PNPLA3 and  other genes associated with MASH and MASH cirrhosis. Next, Scott discusses stellate cells, which he has discussed in earlier episodes of SurfingMASH. Science is increasingly demonstrating how many different types of heterogeneous stellate cells exist. As Scott puts it, these cells "come in many flavors," each of which plays a different role in cell generation or cell death. In fact, the specific therapeutic challenges that present themselves may vary as a patient moves along the pathway from F1 to F2 to F3 to F4. Further, we are learning that there may be several different forms of MASH to present differently at a cellular level. This makes tremendous sense, given that no one drug has proven successful in even a significant majority of patients yet. As the conversation winds down, Scott shares what he describes as a "sobering note" about the state of research funding in America in 2025. As he notes, there are certain kinds of applied and developmental research that private companies do well, but other kinds of basic research that only occur when funded in public and not-for-profit sectors. As a specific example, he cites CRISPR, initially funded publicly and now in the hands of biotech companies, which is used to treat a variety of diseases more effectively than they could have been treated before, if at all. He also comments that a poor early commercial decision slowed the development of statins. 

This weekend's Newsmaker, Indiana University hepatologist and key opinion leader Naga Chalasani, joins Roger Green to discuss Early Experience with Resmetirom To Treat Metabolic-Associated Steatohepatitis with Fibrosis in a Real-World Setting, an article his group published recently in Hepatology Communications. He shares highlights from the paper and points out the one key area in which his group found room for improvement in their initial protocol. Naga and colleagues wrote this paper after learning from Madrigal Pharmaceuticals that they were among the largest early prescribers of resmetirom and, relative to others, had achieved reimbursement with virtually all their patients and a high percentage of patients actually starting the medication. After receiving requests from other states for advice, the group decided to author this paper.In the paper, Naga and colleagues focused on patient selection, care pathway, how IUHealth got the medicine to their patients, and experience with safety and tolerability.In the paper, Naga and colleagues discuss their experiences in prescribing resmetirom for 113 patients in the first seven months after resmetirom's approval. Of these, IUHealth succeeded in achieving reimbursement for 110 of them. Of these patients, 83 initiated therapy, and 16% of those discontinued. In this interview, Naga shares some of the decisions that made the group so successful in the first three areas and identifies one subsequent area where the group found an opportunity for improvement: systematic follow-up with patients after prescribing. He attributes the 16% discontinuation rate to a "prescribe and forget" policy, similar to one that was successful in HCV, where clinicians prescribed without systematic follow-up until blood levels were obtained three months later. With a "prescribe and follow up" policy that includes phone calls at 1 and 3 months, he anticipates discontinuation rates will fall to something akin to the 5% rate in Phase 3 trials. What makes this interview so fascinating is Naga's description of the thinking that went behind specific decisions the group made in terms of patient management and pathway and suggests other options that might work as well. In all, this interview provides an excellent guide for clinics and providers on how to best integrate resmetirom into their practices.

Hepatitis means inflammation of the liver. The liver is a vital organ that processes nutrients, filters the blood, and fights infections. When the liver is inflamed or damaged, its function can be affected. Heavy alcohol use, toxins, some medications, and certain medical conditions can cause hepatitis. However, hepatitis is often caused by a virus. In the United States, the most common types of viral hepatitis are hepatitis A, hepatitis B, and hepatitis C. ​Hepatitis D, also known as “delta hepatitis,” is a liver infection caused by the hepatitis D virus (HDV). Hepatitis D only occurs in people who are also infected with the hepatitis B virus. Hepatitis D is spread when blood or other body fluids from a person infected with the virus enters the body of someone who is not infected. Hepatitis D can be an acute, short-term infection or become a long-term, chronic infection. Hepatitis D can cause severe symptoms and serious illness that can lead to life-long liver damage and even death. People can become infected with both hepatitis B and hepatitis D viruses at the same time (known as “coinfection”) or get hepatitis D after first being infected with the hepatitis B virus (known as “superinfection”). There is no vaccine to prevent hepatitis D. However, prevention of hepatitis B with hepatitis B vaccine also protects against future hepatitis D infection. ​Hepatitis E is a liver infection caused by the hepatitis E virus (HEV). HEV is found in the stool of an infected person. It is spread when someone unknowingly ingests the virus – even in microscopic amounts. In developing countries, people most often get hepatitis E from drinking water contaminated by feces from people who are infected with the virus. In the United States and other developed countries where hepatitis E is not common, people have gotten sick with hepatitis E after eating raw or undercooked pork, venison, wild boar meat, or shellfish. In the past, most cases in developed countries involved people who have recently traveled to countries where hepatitis E is common. Symptoms of hepatitis E can include fatigue, poor appetite, stomach pain, nausea, and jaundice. However, many people with hepatitis E, especially young children, have no symptoms. Except for the rare occurrence of chronic hepatitis E in people with compromised immune systems, most people recover fully from the disease without any complications. No vaccine for hepatitis E is currently available in the United States. (credits CDC)

00:00:00 - Surf's Up: Season 6 Episode 5Host Roger Green briefly describes this episode's three sections and introduces Roundtable guests. The Roundtable panel shares groundbreakers. 00:10:39 - Roundtable: A Deep Dive Into Drug Development, Part OneThe opening portion of this month's roundtable centers around two issues: exciting data for FGF-21s and, more generally, treating patients with cirrhosis. Naim Alkhouri sets the tone in his opening comments, which start by focusing on the exciting SYMMETRY data from efruxifermin and then hones in on FGF-21s and resmetirom in cirrhosis. The rest of the conversation features Jörh Schattenberg, Sven Francque and Naim discussing therapies in development for compensated and decompensating cirrhosis.00;24:44 - Newsmaker: Naga Chalasani on Real-World Experience Prescribing ResmetiromNaga joins Roger to discuss the paper Early Experience with resmetirom to treat Metabolic Dysfunction-Associated Steatohepatitis With Fibrosis in a Real-World Setting from his group at Indiana University, which his group authored and Hepatology Communications recently posted. The paper, based on IU Health's experience with its first 113 resmetirom patients, shares the group's practical experience developing processes to work closely with the specialty pharmacies dispensing resmetirom and, finally, concludes that a more engaged patient management strategy might reduce drug discontinuation to a level comparable with clinical trials.  00:47:21 - Expert: Scott Friedman on Gene Therapy, Diversity of Stellate Cell Types, Other Basic Liver ScienceScott and Roger cover a range of basis science topics in a fast-moving 19-minute discussion. It starts with Scott discussing the increasing acceptance that gene therapy is an acceptable way to treat a range of liver diseases, many of which are orphan or ultra-orphan but, in fact, include potential gene therapies for non-cirrhotic MASH and MASH cirrhosis. He notes that in addition to classic gene therapy, which introduces protective gene variants into the systems of patients with the risky variants, gene therapy is now looking to introduce FGF-21 into patients through genetic modification. From there, the conversation covers CAR-T therapy, the increasing ability to identify many different types of stellate cells and the idea that the most effective therapy for eary fibrosis, advanced fibrosis and cirrhosis might require fundamentally different kinds of interventions. The two final elements are the idea that what we now call "MASH" may be several diseases with different etiologies with similar manifestations and a passionate call for all of us to support maintaining NIH funding in whatever ways we can.01:06:45 - Business ReportAs Roger copes with his laryngitis, AI voices deliver an abbreviated business report 

This week's newsmaker, Yukti Choudhury, Director of Clinical Development at HistoIndex, joins Roger Green to discuss FibroSIGHT, a new HistoIndex service that allows clinicians to use HistoIndex's Second Harmonic Generation (SHG) technology and analytics to determine specific CRN fibrosis level for patients with inconclusive NIT results.  One reason FibroSIGHT is worthy of attention: This is the first time an in-depth analysis of clinical trial biopsy results is being placed at the service of clinical treatment. Another reason: Yukti states that demand for this technique could equal 163,000 cases this year, rising to one million by 2028. The interview starts with Yukti sharing information on her own academic and commercial background and how she came to this role. She describes FibroSIGHT, a service that will provide a highly accurate CRN fibrosis level for patients whose NIT results suggest no clear or consistent finding. Yukti provides practical cues on ordering the test and its reimbursement. Roger shares his long-standing respect for SHG and the clarity it produces. He notes the economic benefit of determining whether a patient has F2 fibrosis, which is indicated for pharmacotherapy, vs.F1, which is not indicated. He sees clear benefit in this analysis. Roger goes on to express concern that any option requiring more biopsies will reduce the number of patients treated, particularly if having this tool encourages payers to require a biopsy as a prerequisite to treatment. He asks whether, over time, HistoIndex might be able to develop a companion analytic to improve these estimates without requiring biopsy. 

The timeline of diagnosis, to possible transplant recipient -- to post-transplant can feel like a whirlwind for patients and caregivers. Marion Marin, a lung transplant recipient, joins the show to discuss how that process went for her! She discusses advocating for yourself, waiting for 'the call' -- and the importance of the community around you when physically and emotionally dealing with a diagnosis! It's the 'Pulmonary Fibrosis' podcast! Brought to you the Wescoe Foundation for Pulmonary Fibrosis and the Pennsylvania IPF Support Network! Find this podcast wherever you get your podcasts! Are you interested in helping advance PF research? If so, consider joining a workgroup! Visit wescoe.org or pfpatientengagement.org for more details!See omnystudio.com/listener for privacy information.

The EVOLVED trial investigated whether early aortic valve intervention could improve outcomes in asymptomatic patients with severe aortic stenosis and myocardial fibrosis. The randomized, multicenter study of 224 patients found no significant difference in all-cause mortality or unplanned aortic stenosis-related hospitalizations between early intervention and guideline-directed conservative management. However, early intervention was associated with lower rates of NYHA class II-IV symptoms and fewer unplanned hospitalizations. The trial highlights the potential symptomatic benefits of early intervention but underscores the need for further research to assess long-term outcomes.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Bristol Myers Squibb is seeking to broaden the use of its CAR T cell therapy, Breyanzi, to address marginal zone lymphoma as a strategy to offset losses from exclusivity. In other news, Boehringer Ingelheim has seen promising results in a Phase III trial for its lung fibrosis drug, randomilast, aimed at progressive pulmonary fibrosis. However, Pliant has experienced a stock decline following the halt of its Phase IIb/III study for idiopathic pulmonary fibrosis. Additionally, Vertex has received FDA approval for its non-opioid pain treatment, while AbbVie has secured approval for a new antibiotic. Bain's acquisition of Tanabe for $3.3 billion is also making headlines. Regeneron is currently in a legal battle with Sanofi over the Dupixent pact, and Equillium's itolizumab is undergoing testing against Humira for ulcerative colitis. On the horizon, Acelyrin and Alumis are joining forces to address immune-mediated diseases, while Eisai is seeking subq approval for Leqembi due to sluggish US sales. Job opportunities are available at ATCC, AbbVie, Regeneron Pharmaceuticals, and Dren Bio.

Interview with Katherine A. Hutcheson, PhD, author of Manual Therapy for Fibrosis-Related Late Effect Dysphagia in Head and Neck Cancer Survivors: The MANTLE Nonrandomized Clinical Trial. Hosted by Paul C. Bryson, MD, MBA. Related Content: Manual Therapy for Fibrosis-Related Late Effect Dysphagia in Head and Neck Cancer Survivors

This week we delve into the world of adult congenital heart disease to review the topic of liver disease in the Fontan patient and specifically, hepatocellular carcinoma (HCC). What is the prevalence of this disease in the Fontan single ventricle adult patient? How effective are scores like the MELD-XI or Fibrosis-4 Index at identification of HCC in the Fontan patient? How should the Fontan adult patient be surveilled for this form of cancer? What evidence is there that earlier identification of HCC is associated with better outcomes? What may prove to be the most important factor in protection of the liver in the Fontan patient? Dr. Yuli Kim, Director of the ACHD program at The University of Pennsylvania shares her deep insights this week into this important topic. DOI: 10.1093/eurheartj/ehad788

Lynette Chambers, a 9-year PAH (pulmonary arterial hypertension) patient, has also been diagnosed with pulmonary fibrosis (PF). She shares her journey, from struggling with daily activities to being admitted to the hospital with severely low oxygen levels. Lynette discusses the emotional challenges of facing a terminal illness and the difficulty of balancing work and family time. Despite the hard reality, Lynette emphasizes the importance of gratitude, making others feel better, and being the best version of oneself. She finds strength in her family, especially her grandchildren, and strives to create lasting memories and make a positive impact on those around her. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. @phacanada

Silicosis is a lung disease caused by inhaling tiny crystalline particles of silica, or silicon dioxide, often linked to work environments like mining, construction, stonework, and sandblasting. The disease leads to symptoms such as coughing, inflammation, and fibrosis (scarring) and is classified under pneumoconioses, a group of lung conditions caused by inhaling dust. Silicosis can be chronic, developing over more than 10 years of exposure; subacute, occurring in two to five years with heavier exposure; or acute, which can happen within months of intense exposure. Although silicosis is irreversible and has no cure, treatments are available to manage symptoms.